Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 159   

Articles published

MRK 59.88 -0.11 (-0.18%)
price chart
Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab
"Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post ...
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for ...  MarketWatch
Sun Pharma, Merck & Co Inc ink pact for Tildrakizumab  Moneycontrol.com
Related articles »  
Merck Announces Positive Phase III Results For Odanacatib; Drug's Safety ...
Merck & Co., Inc. (MRK) announced yesterday, positive results from Phase III trials of its drug odanacatib, used to treat osteoporosis in postmenopausal women.
Related articles »  
3 Reasons Merck & Co., Inc.'s Stock Could Fall
If you were lucky enough to time your purchase of Merck (NYSE: MRK ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater.
Related articles »  
Sun Pharma, Merck & Co enter agreement for Tildrakizumab
The US-based Merck & Co., Inc. and Sun Pharmaceuticals have entered into an exclusive worldwide licensing agreement for Merck's dermatology molecule - tildrakizumab (MK-3222), which is currently under phase 3 registration trials.
Sun Pharma, Merck & Co Inc enter into $80 mn drug licensing pact
New Delhi: Pharma major Sun Pharmaceutical Industries today entered into a licensing agreement with Merck & Co Inc for investigational therapeutic antibody candidate, tildrakizumab to be used for treatment of plaque psoriasis.
Sun licenses Merck anti-inflammatory mAb (MRK)
Mumbai-based Sun Pharma acquires worldwide rights to Merck's (NYSE:MRK) tildrakizumab for use in all human applications for an upfront fee of $80M.
Is it Time to Buy Merck & Co., Inc.'s Stock?
Investors in pharmaceutical giant Merck (NYSE: MRK ) have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and ...
Related articles »  
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Merck (NYSE: MRK ) has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or unresectable ...
Merck Beats Bristol-Myers In Breakthrough Cancer Drug Race  Bidness ETC
FDA OKs Merck melanoma drug, 1st in its class  CNBC
Related articles »  
Bristol-Myers Squibb Co (BMY) Sues Merck & Co., Inc. (MRK) Over Cancer Drug ...
Bristol-Myers Squibb Co (NYSE:BMY) along with Ono Pharmaceutical launched a lawsuit against Merck & Co., Inc. (NYSE:MRK) last Thursday, claiming that the company's new cancer drug Keytruba (which was approved by the FDA the same day) violates ...
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog  NASDAQ
Related articles »  
Merck (MRK): Chasing Down the $1 Billion Specialty Drug
Today, Merck & Co., Inc. (NYSE:MRK) closed just off the 52-week high (61.33) at 59.99, but it was not for lack of effort or headlines.
Jefferies Group Increases Merck & Co. Price Target to $62.00 (MRK)  Ticker Report
Merck & Co. PT Raised to $62.00 at Jefferies Group (MRK)  Watch List News (press release)
Related articles »